Clinical Trial Results

The Effects of Treating Insomnia on Behavioral Weight Loss Outcomes in Survivors of Breast Cancer

NAINTERVENTIONAL Washington D.C., District of Columbia +3 more

RECRUITING

Improving Genetic Counseling for BRCA+ Mothers

NAINTERVENTIONAL Washington D.C., District of Columbia

RECRUITING

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

PHASE1INTERVENTIONAL Beverly Hills, California +4 more

RECRUITING

X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma

PHASE1INTERVENTIONAL Washington D.C., District of Columbia +3 more

RECRUITING

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

PHASE1INTERVENTIONAL Tucson, Arizona +4 more

RECRUITING

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

PHASE3INTERVENTIONAL Mobile, Alabama +4 more

RECRUITING

Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer

PHASE2INTERVENTIONAL Washington D.C., District of Columbia +4 more

RECRUITING

CtDNA Based MRD Testing for NAC Monitoring in TNBC

N/AOBSERVATIONAL Tucson, Arizona +4 more

RECRUITING

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

PHASE3INTERVENTIONAL Daphne, Alabama +4 more

RECRUITING

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

PHASE2INTERVENTIONAL Birmingham, Alabama +4 more

RECRUITING

ETHAN - ET for Male BC

PHASE2INTERVENTIONAL Washington D.C., District of Columbia +4 more

RECRUITING

Older Breast Cancer Patients: Risk for Cognitive Decline

N/AOBSERVATIONAL Washington D.C., District of Columbia

RECRUITING

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

PHASE2INTERVENTIONAL Birmingham, Alabama +4 more

RECRUITING

Mobile Health for Adherence in Breast Cancer Patients

NAINTERVENTIONAL Fairbanks, Alaska +4 more

RECRUITING

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

PHASE3INTERVENTIONAL Mobile, Alabama +4 more

RECRUITING

RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer

PHASE1, PHASE2INTERVENTIONAL Washington D.C., District of Columbia +2 more

RECRUITING

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

PHASE1, PHASE2INTERVENTIONAL Santa Rosa, California +4 more

RECRUITING

Study in Patients With Breast Cancer Leptomeningeal Metastasis

N/AOBSERVATIONAL Washington D.C., District of Columbia +1 more

RECRUITING

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

N/AOBSERVATIONAL Anchorage, Alaska +4 more

RECRUITING

Circulating Tumor DNA

PHASE2INTERVENTIONAL New Haven, Connecticut +4 more

RECRUITING

Abatacept in Immune Checkpoint Inhibitor Myocarditis

PHASE3INTERVENTIONAL Los Angeles, California +4 more

RECRUITING

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

PHASE3INTERVENTIONAL Birmingham, Alabama +4 more

RECRUITING

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

PHASE3INTERVENTIONAL Dothan, Alabama +4 more

RECRUITING

Pan Tumor Rollover Study

PHASE2INTERVENTIONAL Huntsville, Alabama +4 more

RECRUITING

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

PHASE1, PHASE2INTERVENTIONAL Daphne, Alabama +4 more

RECRUITING